Monopar reports Phase 3 trial shows ALXN1840 beats standard care for neurologic Wilson disease

Filed April 20, 2026 · Period ending April 19, 2026 · ~1 min read

Key Changes

• high

  Phase 3 FoCus trial analyses showed ALXN1840 (tiomolibdate choline) delivered greater neurologic benefit than standard of care in Wilson disease patients with neurologic symptoms at baseline.

  Item 8.01 view on EDGAR →
• high

  Results were presented at the American Academy of Neurology Annual Meeting (April 18-22, 2026), marking a key clinical milestone that could support regulatory approval.

  Press Release verify on EDGAR →